ESMO 2023: Sotorasib Plus Panitumumab in Refractory KRAS G12C–Mutated Colorectal Cancer
Posted: 11/07/2023 | By: Melissa E. Fryman, MS

The phase III CodeBreaK 300 trial—findings from which were presented at the ESMO Congress 2023 (Abstract LBA10)—looked at the combination of sotorasib plus panitumumab vs standard care in patients with KRAS G12C–mutated refractory metastatic colorectal cancer. Results were also published in The New England Journal of Medicine.

Question 1 of 5

Sotorasib is a KRAS G12C inhibitor and panitumumab is a(n) ___ inhibitor.

Choose 1